IL301466A - Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic capillary dilatation - Google Patents

Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic capillary dilatation

Info

Publication number
IL301466A
IL301466A IL301466A IL30146623A IL301466A IL 301466 A IL301466 A IL 301466A IL 301466 A IL301466 A IL 301466A IL 30146623 A IL30146623 A IL 30146623A IL 301466 A IL301466 A IL 301466A
Authority
IL
Israel
Prior art keywords
compound
hht
subject
treatment
telangiectasia
Prior art date
Application number
IL301466A
Other languages
English (en)
Hebrew (he)
Original Assignee
Vaderis Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaderis Therapeutics Ag filed Critical Vaderis Therapeutics Ag
Publication of IL301466A publication Critical patent/IL301466A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL301466A 2020-09-30 2021-09-29 Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic capillary dilatation IL301466A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2015536.2A GB2600384A (en) 2020-09-30 2020-09-30 Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
PCT/EP2021/076811 WO2022069552A1 (en) 2020-09-30 2021-09-29 Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Publications (1)

Publication Number Publication Date
IL301466A true IL301466A (en) 2023-05-01

Family

ID=73197201

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301466A IL301466A (en) 2020-09-30 2021-09-29 Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic capillary dilatation

Country Status (13)

Country Link
US (1) US12466839B2 (cg-RX-API-DMAC7.html)
EP (1) EP4221713A1 (cg-RX-API-DMAC7.html)
JP (1) JP7900827B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230080448A (cg-RX-API-DMAC7.html)
CN (1) CN116419924A (cg-RX-API-DMAC7.html)
AU (1) AU2021352108B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023004885A2 (cg-RX-API-DMAC7.html)
CA (1) CA3192433A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000926A1 (cg-RX-API-DMAC7.html)
GB (1) GB2600384A (cg-RX-API-DMAC7.html)
IL (1) IL301466A (cg-RX-API-DMAC7.html)
MX (1) MX2023002996A (cg-RX-API-DMAC7.html)
WO (1) WO2022069552A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2026038045A1 (en) 2024-08-15 2026-02-19 Almac Discovery Limited Crystalline forms of 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one salts and free base

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
JP2008524339A (ja) 2004-12-15 2008-07-10 メルク エンド カムパニー インコーポレーテッド Akt活性のインヒビター
WO2006135627A2 (en) 2005-06-10 2006-12-21 Merck & Co., Inc. Inhibitors of akt activity
CA2656507C (en) 2006-07-17 2012-03-20 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
EP2120951A4 (en) 2006-12-06 2012-02-15 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
JP2011522047A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Akt活性の阻害剤
US8207169B2 (en) 2008-06-03 2012-06-26 Msd K.K. Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D
EP2116237A1 (en) 2008-08-05 2009-11-11 Polichem SA Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
US8957064B2 (en) 2009-02-13 2015-02-17 Bayer Intellectual Property Gmbh Fused pyrimidines
GB0922589D0 (en) 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
MX336865B (es) 2011-04-07 2016-02-04 Bayer Pharma AG Imidazopiridazinas como inhibidores de quinasa akt.
EP3294314A4 (en) 2015-05-15 2019-01-16 Memorial Sloan Kettering Cancer Center USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES
EP3678666B1 (en) 2017-09-07 2025-07-09 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Also Published As

Publication number Publication date
AU2021352108A9 (en) 2024-05-23
EP4221713A1 (en) 2023-08-09
MX2023002996A (es) 2023-05-03
CN116419924A (zh) 2023-07-11
CL2023000926A1 (es) 2023-11-03
JP2023543993A (ja) 2023-10-19
US20240092801A1 (en) 2024-03-21
CA3192433A1 (en) 2022-04-07
JP7900827B2 (ja) 2026-08-05
BR112023004885A2 (pt) 2023-04-18
GB202015536D0 (en) 2020-11-11
US12466839B2 (en) 2025-11-11
AU2021352108B2 (en) 2026-04-02
AU2021352108A1 (en) 2023-05-11
WO2022069552A1 (en) 2022-04-07
KR20230080448A (ko) 2023-06-07
GB2600384A (en) 2022-05-04

Similar Documents

Publication Publication Date Title
EP2935248B1 (en) Compounds and methods for kinase modulation, and indications therefor
CA3052625A1 (en) Compositions and methods for treating heart failure
JP2007502300A (ja) Gsk−3インヒビターおよびその使用
AU2021352108B2 (en) Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
AU2018356430A1 (en) Aromatic sulfonamide derivatives for the treatment of Ischemic Stroke
JP6587637B2 (ja) カルボキサミド誘導体
AU2017281980B2 (en) Wnt inhibitors for use in the treatment of fibrosis
CN110325523B (zh) 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺
JP2011502991A (ja) 骨癌並びに骨癌に伴う骨喪失及び骨痛の処置又は予防のためのcfms阻害物質の使用
JP7713972B2 (ja) 線維性疾患治療用医薬組成物
WO2017157992A1 (en) Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
EP4182311B1 (en) 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases
EA049324B1 (ru) Аллостерические ингибиторы akt для применения в лечении наследственной геморрагической телеангиэктазии
RU2791639C2 (ru) Средство, увеличивающее мозговой кровоток
HK40074977A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
HK40074982A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
WO2001001981A1 (fr) Antagonistes de recepteur de vegf
HK40074980A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
HK40035558A (en) Aromatic sulfonamide derivatives for the treatment of ischemic stroke
HK40011855A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
JPWO2001058489A1 (ja) 術後ストレス予防・治療剤
KR20140038210A (ko) 아나그렐리드를 포함하는 류마티스 관절염의 예방 또는 치료용 약학 조성물